相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Giovanni Targher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
C. Fernandez-Miranda et al.
DIGESTIVE AND LIVER DISEASE (2008)
Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-α control of the acute-phase response
Roxane M. Mansouri et al.
ENDOCRINOLOGY (2008)
Fibrates and future PPAR alpha agonists in the treatment of cardiovascular disease
Bart Staels et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Absence of peroxisome proliferator-activated receptor-γ abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse
Karen M. Tordjman et al.
HYPERTENSION (2007)
Macrophage expression of peroxisome proliferator-activated receptor-α reduces atherosclerosis in low-density lipoprotein receptor-deficient mice
Vladimir R. Babaev et al.
CIRCULATION (2007)
Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
M. Bajaj et al.
DIABETOLOGIA (2007)
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
Vasilios G. Athyros et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice
Rai Ajit K. Srivastava et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2006)
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates
R Shiri-Sverdlov et al.
JOURNAL OF HEPATOLOGY (2006)
Sorting out the roles of PPARα in energy metabolism and vascular horneostasis
P Lefebvre et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia
N Hennuyer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Regulation of human ApoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor α modulation
H Duez et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice
K Wouters et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2005)
Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice
E Ip et al.
HEPATOLOGY (2004)
Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis
A Tailleux et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2003)
The peroxisome-proliferator-activated receptor α agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E
T Fu et al.
BIOCHEMICAL JOURNAL (2003)
Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice
E Ip et al.
HEPATOLOGY (2003)
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice
H Duez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice
K Tordjman et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Defect in peroxisome proliferator-activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting
T Hashimoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
The human peroxisome proliferator-activated receptor a gene: identification and functional characterization of two natural allelic variants
A Sapone et al.
PHARMACOGENETICS (2000)
Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects
DM Flavell et al.
DIABETOLOGIA (2000)
分享论文
